Cyclopropyl Carboxamides, a Chemically Novel Class of Antimalarial Agents Identified in a Phenotypic Screen
Laura M. Sanz,M. Belen Jiménez-Díaz,Benigno Crespo,Cristina De-Cozar,M. Jesus Almela,Iñigo Angulo-Barturen,Pablo Castañeda,Javier Ibáñez,Esther Fernández,Santiago Ferrer,Esperanza Herreros,Sonia Lozano,María Santos Martínez,Lourdes Rueda,Jeremy N. Burrows,Jose F. Garcia-Bustos,Francisco-Javier Gamo +16 more
Reads0
Chats0
TLDR
The biological characterization of this chemical family with the generic name cyclopropyl carboxamides is described, showing that inhibition of their still unknown target has very favorable pharmacological consequences but the compounds themselves seem to select for resistance at a high frequency.Abstract:
Malaria is one of the deadliest infectious diseases in the world, with the eukaryotic parasite Plasmodium falciparum causing the most severe form of the disease. Discovery of new classes of antimalarial drugs has become an urgent task to counteract the increasing problem of drug resistance. Screening directly for compounds able to inhibit parasite growth in vitro is one of the main approaches the malaria research community is now pursuing for the identification of novel antimalarial drug leads. Very recently, thousands of compounds with potent activity against the parasite P. falciparum have been identified and information about their molecular descriptors, antiplasmodial potency, and cytotoxicity is publicly available. Now the challenges are how to identify the most promising chemotypes for further development and how best to progress these compounds through a lead optimization program to generate antimalarial drug candidates. We report here the first chemical series to be characterized from one of those screenings, a completely novel chemical class with the generic name cyclopropyl carboxamides that has never before been described as having antimalarial or other pharmacological activities. Cyclopropyl carboxamides are potent inhibitors of drug-sensitive and -resistant strains of P. falciparum in vitro and show in vivo oral efficacy in malaria mouse models. In the present work, we describe the biological characterization of this chemical family, showing that inhibition of their still unknown target has very favorable pharmacological consequences but the compounds themselves seem to select for resistance at a high frequency.read more
Citations
More filters
Journal ArticleDOI
Antimalarial drug discovery — approaches and progress towards new medicines
TL;DR: The cell-, chemistry- and target-based approaches used to discover new drug candidates that are currently in clinical trials or undergoing preclinical testing are discussed.
Journal ArticleDOI
Recent advances in malaria drug discovery.
TL;DR: Drug discovery efforts directed towards the liver and transmission stages are in their infancy but are receiving increasing attention as targeting these stages could be instrumental in eradicating malaria.
Journal ArticleDOI
Global Phenotypic Screening for Antimalarials
W. Armand Guiguemde,Anang A. Shelat,Jose F. Garcia-Bustos,Thierry T. Diagana,Francisco-Javier Gamo,R. Kiplin Guy +5 more
TL;DR: This review describes the characterization of compounds inhibiting growth of the blood stages of Plasmodium falciparum, explores currently ongoing strategies to develop lead molecules, and endorse the concept of a "malaria box" of publicly accessible active compounds.
Journal ArticleDOI
Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis.
Mathew Njoroge,Nicholas M. Njuguna,Peggoty Mutai,Dennis S.B. Ongarora,Paul W. Smith,Kelly Chibale +5 more
TL;DR: Malaria and the Neglected Tropical Diseases Human African Trypanosomiasis and Schistosomosis Mathew Njoroge, Nicholas M. Njuguna, Peggoty Mutai, Dennis S. B. Ongarora, and Kelly Chibale.
Journal ArticleDOI
Antimalarial drug discovery – the path towards eradication
Jeremy N. Burrows,Emilie Burlot,Brice Campo,Stephanie Cherbuin,Sarah Jeanneret,Didier Leroy,Thomas Spangenberg,David Waterson,Timothy N. C. Wells,Paul Willis +9 more
TL;DR: The current mainstay treatments alongside a selection of emerging new clinical molecules from the portfolio of Medicines for Malaria Venture (MMV) and their partners are highlighted.
References
More filters
Journal ArticleDOI
Human malaria parasites in continuous culture
William Trager,James B. Jensen +1 more
TL;DR: Plasmodium falciparum can now be maintained in continuous culture in human erythrocytes incubated at 38 degrees C in RPMI 1640 medium with human serum under an atmosphere with 7 percent carbon dioxide and low oxygen.
Journal ArticleDOI
Artemisinin Resistance in Plasmodium falciparum Malaria
Arjen M. Dondorp,François Nosten,Poravuth Yi,Debashish Das,Aung Phae Phyo,Joel Tarning,Khin Maung Lwin,Frédéric Ariey,Warunee Hanpithakpong,Sue J. Lee,Pascal Ringwald,Kamolrat Silamut,Mallika Imwong,Kesinee Chotivanich,Pharath Lim,Trent Herdman,Sen Sam An,Shunmay Yeung,Pratap Singhasivanon,Nicholas P. J. Day,Niklas Lindegardh,Duong Socheat,Nicholas J. White +22 more
TL;DR: The overall median clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours in Wang Pha (P<0.001) in each of the two locations as discussed by the authors.
Journal ArticleDOI
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique.
TL;DR: A rapid, semiautomated microdilution method was developed for measuring the activity of potential antimalarial drugs against cultured intraerythrocytic asexual forms of the human malaria parasite Plasmodium falciparum, and results demonstrated that the method is sensitive and precise.
Journal ArticleDOI
Drugs for bad bugs: confronting the challenges of antibacterial discovery
TL;DR: The experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years is shared, and what is learned is looked at and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.
Related Papers (5)
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Matthias Rottmann,Matthias Rottmann,Case W. McNamara,Bryan K. S. Yeung,Marcus C. S. Lee,Bin Zou,Bruce Russell,Bruce Russell,Patrick Seitz,Patrick Seitz,David Plouffe,Neekesh V. Dharia,Jocelyn Tan,Steven Cohen,Kathryn S. R. Spencer,Gonzalo E. González-Páez,Suresh B. Lakshminarayana,Anne Goh,Rossarin Suwanarusk,Timothy Jegla,Esther K. Schmitt,Hans-Peter Beck,Hans-Peter Beck,Reto Brun,Reto Brun,François Nosten,François Nosten,Laurent Rénia,Véronique Dartois,Thomas H. Keller,David A. Fidock,Elizabeth A. Winzeler,Elizabeth A. Winzeler,Thierry T. Diagana +33 more
Chemical genetics of Plasmodium falciparum.
W. Armand Guiguemde,Anang A. Shelat,David Bouck,Sandra Duffy,Gregory J. Crowther,Paul H. Davis,David C. Smithson,Michele Connelly,Julie Clark,Fangyi Zhu,María Belén Jiménez-Díaz,María Santos Martínez,Emily Wilson,Abhai K. Tripathi,Jiri Gut,Elizabeth R. Sharlow,Ian Bathurst,Farah El Mazouni,Joseph W. Fowble,Isaac P. Forquer,Paula L. McGinley,Steve Castro,Iñigo Angulo-Barturen,Santiago Ferrer,Philip J. Rosenthal,Joseph L. DeRisi,David J. Sullivan,John S. Lazo,David S. Roos,Michael K. Riscoe,Margaret A. Phillips,Pradipsinh K. Rathod,Wesley C. Van Voorhis,Vicky M. Avery,R. Kiplin Guy +34 more
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen
David Plouffe,Achim Brinker,Case W. McNamara,Kerstin Henson,Nobutaka Kato,Kelli Kuhen,Advait Nagle,Francisco Adrian,Jason T. Matzen,Paul A. Anderson,Tae-gyu Nam,Nathanael S. Gray,Arnab Chatterjee,Jeff Janes,S. Frank Yan,Richard E. Trager,Jeremy S. Caldwell,Peter G. Schultz,Yingyao Zhou,Elizabeth A. Winzeler +19 more
Artemisinin Resistance in Plasmodium falciparum Malaria
Arjen M. Dondorp,François Nosten,Poravuth Yi,Debashish Das,Aung Phae Phyo,Joel Tarning,Khin Maung Lwin,Frédéric Ariey,Warunee Hanpithakpong,Sue J. Lee,Pascal Ringwald,Kamolrat Silamut,Mallika Imwong,Kesinee Chotivanich,Pharath Lim,Trent Herdman,Sen Sam An,Shunmay Yeung,Pratap Singhasivanon,Nicholas P. J. Day,Niklas Lindegardh,Duong Socheat,Nicholas J. White +22 more